Entrectinib (Rozlytrek) detailed drug explanation and correct usage guide

Entrectinib (trade name: Rozlytrek), its generic name is Entrectinib, is a new broad-spectrum anti-tumor drug that has attracted much attention in recent years. It has been approved in the United States, the European Union, China and other countries, and is mainly used to treat solid tumors and non-small cell lung cancer (NSCLC) with specific gene fusions. The following will introduce you to the drug information and correct method of taking entrectinib in detail.

1. Overview of Drugs

Generic name:Entrectinib(entrectinib)

Product name: Rozlytrek/Rozlytrek

Drug specifications: Provide capsules in two specifications: 100mg and 200mg

Manufacturer: Roche Pharmaceuticals

Enrectinib, as a tyrosine kinase inhibitor (TKI), can accurately inhibit the activity of ROS1, ALK and NTRK and other kinases. It effectively inhibits the growth and spread of cancer cells by interfering with the growth signaling pathways of tumor cells. The drug has been widely proven to have significant effects on a variety of tumor types, especially ROS1-positive non-small cell lung cancer and NTRK gene fusion-positive solid tumors.

2. Correct use method

The recommended dosage of entrectinib is once daily. The specific dosage is as follows:

1. For patients with ROS1 positive non-small cell lung cancer, the recommended dose is 600mg once a day.

2. For patients with solid tumors whose NTRK gene fusion is positive:

1) Adult patients: Take orally daily600mg entrectinib capsules may be taken with or without food until disease progression or unacceptable toxicity occurs.

2) Pediatric patients 12 years old and above: Adjust the dose according to the body surface area (BSA) and take it orally once a day. Specifically: BSA greater than 1.50m² patients take 600mg;BSAat1.11to1.50m< /span>² patients taking 500mg; BSA in 0.91 and 1.10m² took 400mg.

3) Children aged from 1 to 6 months old: Take the dose of 250mg/m² orally once a day.

3. If you miss a dose and it is more than 12 hours before the next dose, the missed dose should be taken as soon as possible. If vomiting occurs after taking the medicine, you need to take it again after vomiting.

3. Precautions for use

Although entrectinib has shown good tolerability in clinical trials, some patients may still experience a series of side effects, including fatigue, constipation, dysgeusia, edema, dizziness, diarrhea, nausea, etc. In addition, the drug may increase the risk of fractures, cause liver toxicity, hyperuricemia, and prolongation of the QT interval. Therefore, during treatment, doctors need to closely monitor the patient's liver function, uric acid level and electrocardiogram QT interval, and adjust the treatment plan according to the patient's specific situation.

In conclusion, entrectinib, as an effective broad-spectrum antitumor drug, provides a new treatment option for patients with tumor types with specific gene fusions. In order to ensure the safety and effectiveness of treatment, patients should strictly follow the correct usage and dosage when taking entrectinib, and closely monitor the efficacy and side effects under the guidance of a doctor. At the same time, there are different versions of entrectinib on the market. Patients should choose according to their own needs, but they must make sure to purchase through formal channels and pay attention to distinguish the authenticity of the medicine.